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The autoimmune rheumatologic disorders mostly have a common genetic path to the au-
toimmunity. Several genes have been associated with rheumatologic disorders; therefo-
re, we are analyzing just the ones in those containing several evidences of the existence 
of association with the risk or protection from autoimmune disorder. The nuclear factor 
kappa beta (NF-kappa B), which regulates the autoimmune and anti-inflammatory res-
ponses, is associated with systemic sclerosis (SS), rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE), just as the CXCR2 e CXCL8 genes. On the other hand, the in-
terleukin-10 (IL-10), which is an anti-inflammatory cytokine, is associated with almost all 
rheumatologic disorders. In this article, we are reviewing the potential roles of these genes 
in the immune system and in several rheumatologic disorders. In relation to IL-10, several 
studies have been carried out, but most of them are controversial – some detected the 
absence of association, and others found association in different genetic polymorphisms. 
Conversely, in relation to NF-kappa B, it was studied just in RA and SLE, and no relevant 
significant analyses were observed. The genetic polymorphisms of the CXCR2 gene were 
associated with SS, but not with RA e SLE. On the other side, the genetic polymorphisms of 
the CXCL8 gene are not associated with SS, but with RA.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Influência dos polimorfismos genéticos (IL10/CXCL8/CXCR2/NFțB) na 
susceptibilidade das doenças reumatológicas autoimunes
Palavras-chave:
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Quimiocinas
Citocinas
NF-kB
r e s u m o
As doenças reumatológicas autoimunes, na maioria das vezes, possuem uma via genética 
comum para a autoimunidade. Vários genes foram associados com as doenças reumato-
lógicas, para tanto iremos analisar somente alguns genes nos quais há várias evidências 
da existência de associação com risco ou proteção de doença autoimune. O fator de trans-
crição nuclear kappa B (NF-kappa B), o qual regula as respostas imunes e inflamatórias, 
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está associado com esclerose sistêmica (ES), artrite reumatoide (AR) e lúpus eritematoso 
sistêmico (LES), assim como os genes CXCR2 e CXCL8. Já a interleucina 10 (IL-10), que é 
uma citocina anti-inflamatória, está associada com quase todas as doenças reumatológi-
cas. Neste artigo, revisamos os potenciais papéis desses genes no sistema imunológico e 
em diversas doenças reumatológicas. Com relação à IL-10, diversos estudos foram realiza-
dos, porém em sua maioria contraditórios - alguns encontraram ausência de associação 
e outros encontraram associação em diferentes polimorfismos do genes. Já em relação ao 
NF-kappa B, somente foi estudado em AR e LES, e não foram observadas análises significa-
tivas relevantes. Os polimorfismos genéticos do gene CXCR2 foram associados com ES, mas 
não estão associados com AR e LES. Já os polimorfismos genéticos do gene CXCL8 não estão 
associados com ES, mas estão associados com AR.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Studies of genetic association seek to determine genetic vari-
ants associated with specific disease states or traits. As more 
studies have been conducted in different complex diseases, 
it became clear that the contribution of individual genes to 
the genetic risk for the disease may be very modest and that 
multiple loci are involved in the mechanism. In this sense, 
the interpretation of genetic association studies in a rare and 
phenotypically heterogeneous disease, such as scleroderma, 
should be performed using strict guidelines. Such studies are 
often limited by a lack of enough statistical power to generate 
reliable and reproducible results, because of small samples 
in case-control studies, genetic heterogeneity, and the extent 
and degree of linkage disequilibrium among genetic markers 
that vary between populations.1
The complex pathophysiology of systemic sclerosis (SSc) 
implies the involvement of genes that affect individually or, 
more likely, jointly, the disease process conduction. Many of 
these genes have been associated with other autoimmune 
diseases such as systemic lupus erythematous (SLE) and 
rheumatoid arthritis (RA), which suggests a common genetic 
pathway for autoimmunity.2
Given the above facts, it is necessary to study the influence 
of the polymorphisms of interleukin-10 (IL-10) genes, the nu-
clear transcription factor kappa of type 1 (NFkB1) B cells, and 
the chemokine receptor 2 and its ligand (CXCR2 and CXCL8) in 
these pathologies. The identification of associations between 
these polymorphisms and systemic sclerosis could impact 
not only in a better understanding of the pathogenesis, but 
also in identifying risk groups for disease development and 
subgroups of patients with better or worse prognoses.
Methodology
A literature search was performed in PubMed database us-
ing the terms “systemic sclerosis and interleukin 10 genes”, 
“systemic sclerosis and CXCL8 polymorphism”, “systemic 
sclerosis and CXCR2 polymorphism”, “systemic sclerosis and 
interleukin 8 gene”, “systemic sclerosis and NFKB1 polymor-
phism”, “Rheumatoid arthritis and interleukin 10 polymor-
phism”, “Rheumatoid arthritis and CXCL8 polymorphism”, 
“rheumatoid arthritis and CXCR2 polymorphism”, “rheuma-
toid arthritis and NFkB1 polymorphism”, “systemic lupus eri-
thematosus and CXCR2 polymorphism” systemic “lupus eri-
thematosus and CXCL8 polymorphism”, and “systemic lupus 
erithematosus and IL-10 polymorphism”. All articles found 
were assessed, and data included in this review include the 
results of association studies, both positive and negative, 
since 1991, the year of publication of the first article on the 
topic. The exclusion criterion used was the presence of micro 
satellite-related studies.
Function of proteins and their respective genes 
NFkB 
The kappa B nuclear transcription factor of B cells (NF-kappa 
B) consists of a group of proteins involved in the expression 
of a wide variety of genes that are involved in the regulation 
of immune and inflammatory responses.3 Genes that are acti-
vated by NF-kappa B include proinflammatory cytokines, che-
mokines and adhesion molecules. Some genes regulated by 
NF-kappa B, such as tumour necrosis factor alpha (TNF-Į) and 
interleukin-1 beta (IL-1ȕ) also directly activate NF-kappa B to 
amplify and increase the primary inflammatory response. 
The activation of NF-kappa B by B or T-cell receptors is also 
required for the proliferation induced by antigen, cytokine 
production and survival of T and B cells.4
So far, five members of the NFkB family have been identi-
fied: NFkB1 (p105/p50), NFkB2 (p100/p52), RelA (p65), RelB and 
RelC. NFkB1 gene is located in the region 4q23-q24 and con-
sists of 24 exons and introns. The gene encoding P105 protein 
is a cytoplasmic non-DNA binding molecule, while the gene 
encoding p50 protein is a DNA binding protein and corre-
sponds to the N-terminal of p105 (OMIM, 164.011). The NFKB2 
gene is located on the long arm of the chromosome, located in 
the region 10q24, and encodes proteins P100 and P52 (OMIM, 
164.012). On the other hand, the RelA gene (NFKB3) is locat-
ed in the 11q12-q13 region with 10 and encodes p65 protein 
(OMIM, 164.014); the RelB gene is located on chromosome 19 
(OMIM, 604.758, MI-12,248) and THE cRel gene is located in the 
2p13-p12 region.5
Furthermore, the functions of NFkB1 (P105) and NFkB2 
(p100) are different, although their structures are similar. 
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Studies have reported that the processing of P105 protein 
to p50 is essential, this event being essential for peripheral 
lymphoid tissue organogenesis and B-cell development. An-
other important aspect is that the induction of the process-
ing of protein p100 is regulated by a subset of ligands that 
activate NF-kappa B.6 NF-kappa B provides a key mechanistic 
link between inflammation and tumour. Indeed, several in-
flammatory cytokines, chemokines, products of necrotic cells, 
bacteria and viruses stimulate the activation of NF-kappa B. 
Conversely, proteins of NF-kappa B increase the expression of 
some cellular genes involving cytokines, chemokines, the ma-
jor histocompatibility complex (MHC) and receptors needed 
for neutrophil adhesion and migration.7
One study examined the activation of NFkappa B in the 
synovium of patients with rheumatoid arthritis, suggesting a 
role in controlling the inflammation.8 It is known that rheu-
matoid arthritis is a complex disease with contributions of 
systemic autoimmunity and local inflammation. However, 
the activation of NF-kappa B is significantly decreased in pa-
tients with systemic lupus erythematosus.9 These findings 
indicate that the mechanism of regulation of NF-kappa B is 
different between these autoimmune diseases.
NF-kappa B is found in the cytoplasm of immune cells, in 
association with accessory proteins. Its activation mode var-
ies according to the type of immune cell, with its activation 
state or developmental stage.10 Furthermore, NF-kappa B is 
normally prevented from entering the nucleus of peripheral 
lymphocytes (T cells), because its subunits are strongly linked 
to the inhibitory protein. After cell induction by cytokines, a 
series of biochemical changes, including phosphorylation, 
ubiquitination and, then, degradation by the proteasome, oc-
curs. When NF-kappa B is able to translocate to the nucleus, 
where it binds to DNA within minutes, this factor leads to the 
expression of different target genes.11
The nuclear activation and translocation of the classical 
pathway of NF-kappa B dimers (particularly p50-RelA) are as-
sociated with an increased transcription of genes encoding 
chemokines, cytokines, adhesion molecules, enzymes that 
produce secondary inflammatory mediators and inhibitors 
of apoptosis.12 These molecules are important components 
of the innate immune response and are required for the mi-
gration of inflammatory and phagocytic cells into tissues 
where NF-kappa B was activated in response to infection or 
injury. An extensive list of bacteria and bacterial products ac-
tivate NF-kappa B in macrophages and other cell types. For 
example, enteroinvasive bacteria can activate NF-kappa B in 
intestinal epithelial cells, a process leading to the production 
of inflammatory mediators including chemokines. These pro-
teins lead to the recruitment of inflammatory and phagocytic 
cells to the site of infection. Moreover, there are also indirect 
pathways that lead to the activation of NF-kappa B, result-
ing in the release of IL-1 and in the activation of the classical 
pathway of NF-kappa B in adjacent cells.13
Chemokines 
Chemokines are chemotactic proinflammatory cytokines that 
recruit leukocytes to sites of inflammation, but which also 
play prominent roles in tumour growth, angiogenesis, wound 
healing/tissue sclerosis and autoimmunity.14 The chemokines 
constitute a large family of small proteins (7-15 kDa), struc-
turally related to heparin binding proteins that can mediate 
leukocyte-endothelial interactions and the transmigration of 
cells. The priming and progression of rheumatic diseases in-
volve multiple chemokines and inflammatory cells, such as 
T cells, macrophages, dendritic cells, eosinophils, and mast 
cells. The complex interactions between inflammatory cells 
and chemokines stimulate the overproduction of extracellu-
lar matrix protein synthesis by fibroblasts. Therefore, chemo-
kines have critical importance in the pathogenesis of these 
diseases.15
The members of the family of chemokines are divided into 
four groups, according to the spacing of their first two cyste-
ine residues. CXCL8 is a member of the CXC chemokine fam-
ily that shows high binding affinity to CXCR1 (IL-8 receptor 
type 1) and CXCR2 (IL-8 receptor type 2). Although CXCR1 is 
selectively activated only by CXCL8, CXCR2 answers to sev-
eral additional chemokines. The common denominator for all 
chemokines that activate CXCR2 is the Glu-Leu-Arg (ELR) se-
quence at the amino terminal, which appears to function as 
a recognition sequence for receptor binding and activation.16 
The first investigations were focused on the effect of CXCL8 in 
neutrophils, which respond with calcium mobilization, actin 
polymerization, enzyme release, chemotaxis and a weak re-
spiratory burst.17 Despite similar affinities for CXCL8 and sim-
ilar receptor numbers of CXCR1 and CXCR2, the neutrophil 
chemotaxis is mediated primarily by CXCR1. However, despite 
the fact that CXCR2 is associated with the inhibition form 
of G-protein alpha subunit (GĮi2), a study showed that both 
CXCR1 and CXCR2 are coupled to inhibitory G (Gi) protein in 
neutrophils where GĮi2 is abundant. Therefore, it was shown 
that the coupling of the CXCL8 receptor is not restricted to Gi. 
At least under conditions in which GĮi4 and GĮi6 were overex-
pressed, these G proteins were able to function as alternative 
elements of transducer signalling of CXCL8-mediated cellular 
response.18
Thus, CXCL8 is activated by both CXCR1 and CXCR2 on 
endothelial cells. The two receptors use different signalling 
transduction cascades that result in the activation of small G 
proteins and invoke responses that deserve to be investigat-
ed. These responses of chemokines mediated by endothelial 
cells may contribute to an increase of the vascular permeabil-
ity and leukocyte adhesion, as was observed during acute in-
flammation episodes, on the one hand, and to the migration 
and proliferation of endothelial cells during the angiogenic 
process, on the other hand.19 The activity of NF-kappa B may 
be necessary in multiple steps during this cascade, both for 
the induction of protein synthesis or by direct interaction in 
the cytoplasm.20
Indeed, chemokines and their receptors are crucial fac-
tors for tissue damage in SSc, potentially directing the migra-
tion of proinflammatory cells to the affected areas. Increased 
levels of CXCL8 protein in skin biopsy and bronchoalveolar 
lavage fluid from patients with SSc have been observed.21 A 
study mentioned that scleroderma skin fibroblasts cultured 
in vitro produce more CXCL8 than normal fibroblasts. Serum 
concentrations of CXCL8 were significantly higher in SSc pa-
tients versus controls (healthy subjects).22
In patients with fibrosing alveolitis (FA), an increase in the 
secretion of CXCL8 by alveolar macrophages (AM) and mono-
cytes was observed. It is known that in scleroderma patients 
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there is a predisposition to the development of FA, but the 
CXCL8 secretion by AM in SSc patients without FA was higher 
than in normal individuals, and lower than in patients with 
fibrosing alveolitis associated with SSc (FASSc). This finding 
suggests that the increased secretion of CXCL8 in FASSc by AM 
is not constitutive. It is possible that the response of CXCL8 to 
initial factors of the disease may be different in those patients 
who will develop FA compared with those who will not.23
Another study showed that patients with chronic idio-
pathic urticaria (CIU) exhibit a pattern of altered chemokine 
secretion that is potentially linked to a chronic inflamma-
tory state. Analyzing the CXCL8 gene regulation assessed by 
mRNA and protein levels in serum, the study indicated a high 
response capacity from monocytes, thereby contributing to 
the creation of a proinflammatory environment. These find-
ings suggest that the innate immune system, by means of 
chemokines and monocytes, can lead to immune activation.24
Cytokines 
Cytokines are essential mediators of the immune system 
with a broad set of functions, ranging from the regulation of 
inflammation to cell activation, proliferation or differentia-
tion. Cytokines can also promote collagen deposition and fi-
brosis; in this way, many studies are focusing on their role as 
mediators of SSc, describing changes in their concentrations 
or in the balance between T helper type 1 (Th1) and type 2 
(Th2) cytokine levels.25
Cytokines include the interleukins, which are proteins 
(polypeptides) involved in the communication among leu-
kocytes. The activities of interleukins can be summarized in 
the recognition of foreign antigens by T cells, amplification of 
the proliferation of activated T cells, and attraction of macro-
phages and identification of effective mechanisms for phago-
cytosis of microorganisms. Each interleukin acts on a limited 
and specific group of cells expressing appropriate receptors 
for each of these proteins. Interleukin-10 (IL-10) inhibits the 
production of Th1 cytokine, suppresses macrophage function 
and activates B lymphocytes.26
Interleukin-10 (IL-10) is a potent anti-inflammatory cyto-
kine which plays a crucial role – often an essential one – in 
preventing inflammatory and autoimmune diseases. The de-
ficiency or abnormal expression of IL-10 can increase the in-
flammatory response to microbial challenge, leading to the 
development of inflammatory bowel disease and to a number 
of autoimmune disorders. Thus, the decreased expression of 
IL-10 can increase the pathogens during an acute infection, 
but also exacerbates the inflammatory response, resulting in 
immunopathology and tissue damage.27
There is a wide variation in the production of IL-10 among 
individuals; studies on twins suggest that up to 75% of the 
variability is due to genetic factors. The production is con-
trolled at the transcriptional level and some variations may 
be explained by two microsatellite polymorphisms (IL-10G 
and IL-10R) in the promoter region.28 Eleven single nucleotide 
polymorphisms (SNP) have also been described in the pro-
moter region, three of which are in the proximal 1.3 kb [1082 
(G/A), 819 (C/T) and 592 (C/A)]; and seven in the distal region 
1.3-4 kb, three of which [3575 (T/A), 2849 (G/A) and 2763 (C/A)] 
have the same allele frequency.29,30 In normal Caucasian sub-
jects, the distal AA/GA haplotype was more frequent in those 
who produced less IL-10.29 In African-Caribbean SLE patients, 
the frequency of the A allele of polymorphism 2,763 was low-
er. There are no other associations with rheumatic diseases 
reported with SNPs in the distal region. SNPs 819 and 592 are 
in linkage disequilibrium.30 Furthermore, only three haplo-
types are common in Caucasian subjects: GCC, ACC and ATA; 
GTA is more common in southern China.31 GCC/GCC genotype 
is more common in those who produce the highest levels of 
IL-10, while ATA/ATA genotype predominate in low producers 
of IL-10.29
Traditionally, cytokine genes and receptors have attract-
ed great interest as plausible genetic risk factors for autoim-
mune disease. Considering that the production of cytokines 
is genetically regulated, it was hypothesized that single nu-
cleotide polymorphisms (SNPs) near cytokine genes may be 
relevant to the development of SSc.32 However, studies have 
failed to show positive results and, in some cases, the as-
sociations described by some authors were not confirmed 
in other independent populations.33,34 These contradictory 
results can be attributed to several factors. First, there are 
studies using small samples; therefore, they are not able to 
represent a true association, due to type II error.35 Second, 
the SNPs studied may not have a causal role in the patho-
genesis of SSc, but could only be relevant to the progression 
or expression of disease.36 Third, each SNP may not have a 
main noticeable effect on the independent risk of disease, 
but its effect may be dependent on other genetic variants 
(gene-gene interaction).37
The gene for IL-10 is a likely candidate to be studied in 
the pathogenesis of SSc, not only due to its anti-inflammatory 
properties, but also because it protects against fibrosis. In ad-
dition, IL-10 reduces the production of collagen and fibronec-
tin from fibroblasts.38 Furthermore, the functional relevance 
of SNP in the proximal 5’ region of IL-10 gene is well defined.39
Genetic evidence in rheumatic diseases 
CXCL8 
Several polymorphisms of CXCL8 gene were studied in re-
lation to rheumatic diseases (Table 1). In patients with SSc, 
genetic polymorphisms (+293 G/T) (+678 T/C), (-353 A/T) and 
(-251 T/A) were evaluated, however none of these polymor-
phisms exhibited association with the disease.40-42 An asso-
ciation was only found when analyzing the gene-gene inter-
action between the polymorphism of CXCL8 (-353 A/T) gene 
with CCL541 gene and between the polymorphism of CXCL8 
(-251 A/T) gene with CXCR2 gene.42
In SLE, a study showed a strong association between SNP 
rs2227306 of CXCL8 gene and the disease, demonstrating a 
risk factor.45 But four previous studies had not shown an as-
sociation with the disease, and only two of these had a power 
similar to the one of Sandling et al.46,47 These polymorphisms 
have not been studied in rheumatoid arthritis (RA), although 
other polymorphisms were studied and associated with this 
disease. The polymorphism (-781 C/T) of CXCL8 gene is asso-
ciated with the onset of the disease, the CC homozygote be-
ing a risk factor.43 On the other hand, the polymorphism (-767 
A/G) is not associated with risk of developing the disease, but 
the AA homozygote is associated with the development of the 
disease at an early age.44
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CXCR2 
So far, in patients with SSc, no genetic studies were per-
formed on the association of CXCR2 gene polymorphism, but 
other studies have analyzed the presence of polymorphism 
in SSc, SLE, SS and RA (Table 2). Therefore, a study evaluated 
the susceptibility of the polymorphism (-786 C/T) of CXCR2 
gene in patients with rheumatoid arthritis, but no association 
was found between the gene and the disease. Likewise, no 
association was found when evaluating the correlation of this 
same polymorphism in patients with SLE and SSc.41,48 How-
ever, subsequent studies in SSc patients that examined an-
other CXCR2 gene polymorphism obtained different results. 
First, the polymorphism (+1208 C/T) was analyzed in British 
patients, yielding a strong association with TT homozygous 
gene with a risk factor for the disease.40 Contrary to these 
findings, in southern Brazil we found a strong association 
of CC homozygote of this same polymorphism in relation to 
disease susceptibility.42 This observed difference might be ex-
plained by the great Brazilian miscegenation due to immigra-
tion of Africans and Europeans in the past, which resulted in 
a highly diverse population.49
NFkB1
The polymorphism of NFkB1 was evaluated in several rheu-
matic diseases (Table 3). In SSc patients, no study found an 
association with the insertion/deletion of ATTG aminoacids 
at position -94 of NFkB1 gene. However, one study demon-
strated a protective factor for the disease with the interaction 
of the homozygous polymorphism for insertion (insertion 
/ insertion) of ATTG in NFkB1 gene (-94 ins/del ATTG) with 
CC homozygous polymorphism of IL-10 gene (- 819). We also 
demonstrated as a risk factor for SSc the interaction of the 
NFkB1 heterozygous gene (insertion/deletion) with the CC ho-
mozygous polymorphism of IL-10 (-592) gene.50
Table 1 – Analysis of CXCR8 polymorphism in rheumatologic diseases
Gene Disease Polymorphism Results Number (N) Study (Ref.)
Patients Controls
CXCL8
Systemic 
sclerosis
(+)293 G/T no association 128 194 Renzoni et al. 200040
(+)678 T/C no association 128 194 Renzoni et al. 200040
(-)353 A/T association with gene CCL5-403 G/A 
(p=0.039)
99 198 Lee et al. 200741
no association 128 194 Renzoni et al. 200040
(-)251T/A association with gene/cxcr2+1208 C/T 
(p<0.001)
151 147 Emonts et al. 201143
Rheumatoid 
arthritis
(+)781 C/T CC homozygote (p<0.0001; rs2227306) 376 463
3’UTR 2767 A/G AA homozygote (p=0.02; rs10938092) 199 130 Lo et al. 200844
Systemic lupus 
erythematosus
rs46941 78 C/A C allele (OR=1.26; P<0.001) 826 1310 Sendling et al. 201145
no association 150 130 Hang et al. 200646
(-)353 A/T; (+)781 C/T no association 500 481 Sanchez et al. 200647
Table 2 – Analysis of CXCR2 polymorphism in rheumatologic diseases
Gene Disease Polymorphism Results Number (N) Study (Ref.)
Patients Controls
CXCR2
Systemic sclerosis
(-)786 C/T no association 14 242 Kato et al., 200048
CC homozygote (OR=1.7; p=0.04) 99 198 Lee et al., 200741
(+)785 C/T CC homozygote (OR=2.33; p=0.01) 128 194 Renzoni et al., 200040
(+)1208 C/T TT homozygote (OR=2.67; p=0.003) 128 194 Renzoni et al., 200040
CC homozygote (or=2.76; p=0.001) 151 147 Salim et al., 201242
(+)1440 G/A no association 128 194 Renzoni et al., 200040
Rheumatoid arthritis
(-)786 C/T no association 146 242 Kato et al., 200048
Systemic lupus 
erythematosus
(-)786 C/T no association 80 242 Kato et al., 200048
Sjögren syndrome
(-)786 C/T no association 12 242 Kato et al., 200048
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In RA patients, no direct association of gene with the dis-
ease was found,51-53 but a study showed that the homozygous 
genotype with deletion of ATTG (Del/Del) in NFkB1 gene is at 
high risk for cardiovascular events in patients with RA com-
pared with patients who were homozygous for gene inser-
tion.54 Another study stratified patients according to NFkB1 
genotype and evaluated their combination with FCRL3 poly-
morphism, observing a susceptibility to the disease in pa-
tients heterozygous (Ins/Del) to NFkB1 gene.53
According to one study, patients with SLE have a lower 
risk of developing the disease in case of an incidence of the 
heterozygote (insertion / deletion) of NFkB1 gene (-94 ins/del 
ATTG).55 But another study found no association of NFkB1 
gene in patients with SLE.51
Interleukin-10 
Different studies have linked several polymorphisms of IL-
10 in rheumatic diseases (Table 4). A meta-analysis in pa-
tients with SSc reported that the -819 polymorphism (C/T) 
of IL-10 is associated with susceptibility to the develop-
ment of SSc. These authors observed that the C allele at 
-819 locus of IL-10 may be a risk factor, and that the A al-
lele of 3575 polymorphism may contribute to the disease, 
especially in Caucasian subjects.58 However, other studies 
individually conducted have not achieved the same results. 
In the west of Scotland, there was no statistical difference 
in genotype distribution of IL-10 between patients and con-
trols, but, interestingly, patients with diffuse disease had a 
low frequency of GCC/GCC genotype (which is associated 
with a high production of IL-10), suggesting that the inheri-
tance of the IL-10 genotypes may be one of the molecular 
events that determine the clinical phenotype.34 In Italy36 
and Turkey,57 the GCC haplotype exhibited more expression 
in SSc patients than in controls, and, in southern Brazil, we 
noted that the GCC/GCC genotype proved to be a risk fac-
tor for the development of the disease.48 But another study 
conducted in Italy found no such associations with the 
disease.33 In Japan, other polymorphisms were evaluated: 
-3575 A/T, -2849 A/G and -2763 A/C. The frequency of the AC 
heterozygote at position 2763 was higher in SSc patients 
than in controls. On the other hand, patients with diffuse 
scleroderma had the lowest frequency of the CC homozy-
gote when compared with healthy controls. In Caucasian 
subjects, the frequency of the AA homozygote at positions 
-3575 and 2763 was higher in SSc patients compared with 
controls.60
Some studies in patients with rheumatoid arthritis 
found no association of IL-10 polymorphisms with the dis-
ease.63 However, some studies observed a protective factor 
of this gene in these patients. Paradowska-Gorycka et al. 
69 (2010) emphasized that the G allele of SNP-1082 of IL-10 
and the C allele of SNP -592 were more common in controls 
than in patients with RA. De Paz et al.67 (2010) also found 
a protective factor in this gene, but in the AA haplotype of 
SNP-1082 of IL-10.
On the other hand, all other studies observed a suscep-
tibility factor for the disease. Ying et al.68 (2011) reported a 
higher frequency of the C allele of SNP-592 C in patients 
with RA, agreeing with Hee et al.64 (2007), who also found 
this result. Conversely, Pawlik et al.62 (2005) reported a 
higher frequency of the GG haplotype of SNP-1082 GG in 
patients with RA. Ates et al.57 (2008) and Cantagrel et al.66 
(1999) also mentioned SNP-1082 as a susceptibility factor 
for the disease. Some studies performed with other poly-
Table 3 – Polymorphism analysis of NFKB1 -94ins/del ATTL (s28362491) in rheumatologic diseases
Gene Disease Results Number (N) Study (Ref.)
Patients Controls
NFKB1-94 ins/
del ATTG 
(rs28362491)
Systemic 
sclerosis
association of ATTG (homozygous) insertion 
with gene IL-10 (-819)CC and (-592)CC
151 147 Salim et al., 201350
Rheumatoid 
arthritis
no association 272 264 Orozco et al., 200951
no association 458 657 Dieguez-Gonzalez et al., 200952
association of heterozygous gene (ins/Del) 
with gene FCRL3 (-169)GG (p=0.003)
592 646 Martinez et al., 200653
association of homozygous gene for deletion 
(Del/Del) with risk for cardiovascular 
events (OR=1.76; p=0.03)
1437 * Lopez-Mejias et al., 200254
Systemic lupus 
erythematosus
protection with heterozygote gene (Ins/del) 
(OR=0,52; P=0,012)
224 256 Gao et al., 201255
No association 181 264 Orozco et al., 200952
Ankylosing 
spondilitis
no association 205 200 Kim et al., 200556
*The study only accessed the interaction among patients
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morphisms in Brazilian population found no association 
with rheumatologic diseases.70
Analyzing the haplotypes and genotypes of IL-10 in 
rheumatic diseases, we found that the GCC/GCC genotype 
is associated with SSc, RA and SLE. Conversely, the ACC 
haplotype is associated with SS and SLE; and the GCC hap-
lotype is associated with SSc and RA. Moreover, in patients 
with JIA, there was a protection with GCC genotype.
Conclusion 
Genetic factors may contribute to the failure of tolerance 
and to the development of autoimmune responses. In this 
paper, we presented how the NFkB1, IL-10, CXCL8 and CXCR2 
genes could be involved in the initiation and progression of 
autoimmune rheumatic diseases. There are still many diver-
gences among studies, but this is because the populations 
are genetically different. Therefore, the identification of indi-
vidual components of these genes as the key to a particular 
disease and the development of inhibitory compounds able 
of performing a specific activity will constitute a promising 
and challenging task for the future.
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Table 4 – Analysis of interleukin-10 (IL-10) polymorphism in rheumatologic diseases
Gene Disease Polymorphism Results Number (N) Study (Ref.)
Patients Controls
IL-10
Systemic 
sclerosis
(-)1082 G/A; (-)819 C/T; 
(-)592 C/A
association of GCC haplotype with 
diffuse form (OR=1.84; p=0.04)
161 94 Beretta et al., 200736
GCC/GCC genotype (OR=1.87; p=0.019 151 147 Salim et al., 201348
protection of GCC/GCC genotype with 
diffuse form (OR=0.10; p=0.005)
51 94 Crilly et al., 200334
association of GCC/GCC genotype 
(OR=5.07; p=0.002)
45 150 Ates et al., 200857, 
Peng et al., 201258
(-)590 A/C no association 242 242 Beretta et al., 200736
(-)3575 A/T association of AA haplotype with limited 
form (OR=3.60; p=0.0002)
105 143 Hudson et al., 200560
no association 78 692 Matuzzi et al., 200733
(-)2849 A/G association of GG haplotype with limited 
form (OR=0.53; p=0.03)
105 143 Hudson et al. 200560
(-)2763 A/C association of AA haplotype with limited 
form (OR=3.50; p=0.003) and diffuse 
form (OR=3.0; p=0.03)
105 143 Hudson et al., 200560
Rheumatoid 
arthritis
(-)1082 G/A; (-)819 C/T; 
(-)592 C/A
association of GCC (OR=1.46; p=0.006) 
and ACC (OR=1.43; p=0.011) haplotypes
98 122 Ates et al., 200857
association of ACC haplotype in patients 
positive for rheumatoid factor IgA 
(OR=1.6; p=0.05)
234 238 Hajeer et al., 199861
association of GCC/GCC genotype 
(OR=2.18; P<0.005)
95 104 Pawlik et al., 200562
no association 222 398 Gambhir et al., 
201063
(-)1087 G/A; (-)824 C/T; 
(-)597 C/A
ATA haplotype associated with low 
production of IL-10 (P<0.05)
84 95 Hee et al., 200764
(-)2849 A/G association of G allele in patients 
positive for rheumatoid factor IgG 
(P<0.001)
283 1220 Lard et al., 200365
(-)1082 G/A no association (rs1800896) 376 463 Emonts et al., 201143
no association 108 128 Cantagrel et al., 
199966
protection with AA genotype (OR=0.56; 
p=0.006)
162 373 de Paz et al., 201067
(-)819 C/T no association (rs3021097) 376 463 Emonts et al., 201143
(-)592 C/A association of A allele (OR=1.31; p=0.008) 164 196 Ying et al., 201168
association of CA genotype (OR=46.34; 
P<0.001)
244 106 Paradowska-
Gorycka et al., 
200869
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